Lipigon Pharmaceuticals AB (publ)
STO: LPGO.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Johan Liwing
- Employees
- 6
- Headquarters
- Umeå, Sweden
- IPO year
- 2021
- Market cap
- SEK 2.2M
- Website
- https://www.lipigon.se
Loading LPGO…
Loading profile data…Frequently asked questions about LPGO
What does Lipigon Pharmaceuticals AB (publ) (LPGO.ST) do?
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; t...
Where does LPGO.ST trade?
Lipigon Pharmaceuticals AB (publ) (LPGO.ST) trades on the Stockholm Stock Exchange.
What sector is LPGO.ST in?
Lipigon Pharmaceuticals AB (publ) (LPGO.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lipigon Pharmaceuticals AB (publ)?
Johan Liwing is the chief executive officer of Lipigon Pharmaceuticals AB (publ) (LPGO.ST).
Where is Lipigon Pharmaceuticals AB (publ) headquartered?
Lipigon Pharmaceuticals AB (publ) is headquartered in Sweden.
Does LPGO.ST pay a dividend?
Lipigon Pharmaceuticals AB (publ) (LPGO.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LPGO.ST go public?
Lipigon Pharmaceuticals AB (publ) (LPGO.ST) completed its initial public offering in 2021.